Discover is an early stage clinical trial designed to quickly test whether the study drug in Alzheimer’s disease (AD) hit their targets and work as scientists intended. The Discover Study is a randomized, double-blind, placebo controlled study. “Randomized” means that it will be determined by chance which of the treatment groups you will be assigned. “Double-blind” means that neither the participant nor the research team will know whether a participant is taking the placebo or the study drug. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).
In the Discover trial, scientists will be testing the study drug Posiphen, which may delay AD onset or slow the progression of AD- related brain damage by targeting the build-up of amyloid plaques. Discover is a Phase 1b study. It means that participants will help to determine the side effects of the drug and how the drug is broken down by the human body (pharmacokinetics). The primary outcome measures of this study are safety and tolerability, pharmacokinetics measured on serum and cerebrospinal fluid, and the dose effect on the production rate of Beta Amyloid 40 which is commonly found in AD patients.